The Only Monthly Membership With a Positive ROI!
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
The Only Monthly Membership With a Positive ROI!
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Comments
Close menu
Loading...
Foghorn Therapeutics
FHTX
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$8.01
0.5
6.66%
At Close: -
$8.01
0
0.00%
After Hours: Aug 23, 4:00 PM EDT
15 minutes delayed
Get Report
Comment
Foghorn Therapeutics (FHTX) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Foghorn Therapeutics (NASDAQ:FHTX) Stock
Foghorn Therapeutics Stock (NASDAQ: FHTX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, August 19, 2024
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
Avi Kapoor
Foghorn Therapeutics shares are trading highe...
Benzinga Newsdesk
Evercore ISI Group Initiates Coverage On Fogh...
Benzinga Newsdesk
Monday, August 12, 2024
HC Wainwright & Co. Reiterates Buy on Foghorn...
Benzinga Newsdesk
Friday, August 09, 2024
Wedbush Reiterates Outperform on Foghorn Ther...
Benzinga Newsdesk
Thursday, August 08, 2024
Foghorn Therapeutics Q2 2024 GAAP EPS $(0.45)...
Benzinga Newsdesk
Wednesday, July 10, 2024
Foghorn Therapeutics Says Flagship Pioneering...
Benzinga Newsdesk
Monday, May 20, 2024
Foghorn Prices $110M Registered Direct Offeri...
Benzinga Newsdesk
Tuesday, May 07, 2024
HC Wainwright & Co. Reiterates Buy on Foghorn...
Benzinga Newsdesk
Wednesday, May 01, 2024
HC Wainwright & Co. Reiterates Buy on Foghorn...
Benzinga Newsdesk
Tuesday, April 16, 2024
Foghorn Therapeutics Has Appointed Kristian H...
Benzinga Newsdesk
Wednesday, April 10, 2024
Wedbush Reiterates Outperform on Foghorn Ther...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Foghorn...
Benzinga Newsdesk
Tuesday, April 09, 2024
Foghorn Therapeutics Presents New Preclinical...
Benzinga Newsdesk
Friday, March 08, 2024
Wedbush Reiterates Outperform on Foghorn Ther...
Benzinga Newsdesk
Thursday, March 07, 2024
Foghorn Therapeutics: Q4 Earnings Insights
Benzinga Insights
Foghorn Therapeutics Reports FY23 Collaborati...
Benzinga Newsdesk
Tuesday, March 05, 2024
Foghorn Therapeutics To Present New Preclinic...
Benzinga Newsdesk
Thursday, February 08, 2024
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
Why Foghorn Therapeutics (FHTX) Stock Is Exploding Higher
Henry Khederian
Foghorn Therapeutics shares are trading highe...
Benzinga Newsdesk
Foghorn Announced That Eli Lilly Has Selected...
Benzinga Newsdesk
Wednesday, January 17, 2024
Foghorn Therapeutics Appoints Stephen DiPalma...
Benzinga Newsdesk
Monday, January 08, 2024
Foghorn Therapeutics Highlights Clinical Prog...
Benzinga Newsdesk
Wednesday, January 03, 2024
Foghorn Therapeutics CFO Allan Reine To Depar...
Benzinga Newsdesk
Friday, December 01, 2023
Foghorn Therapeutics Says Clinical Data From ...
Benzinga Newsdesk
Monday, November 13, 2023
Morgan Stanley Maintains Equal-Weight on Fogh...
Benzinga Newsdesk
Tuesday, October 24, 2023
Foghorn Therapeutics To Present At Upcoming C...
Benzinga Newsdesk
Friday, October 13, 2023
Foghorn Therapeutics Announces Clinical Data ...
Benzinga Newsdesk
Tuesday, October 10, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
Wednesday, October 04, 2023
Foghorn Therapeutics To Present Clinical And ...
Benzinga Newsdesk
Thursday, September 14, 2023
Foghorn Therapeutics Chief Medical Officer Awarded $1.93M Worth of Stock Options
Benzinga Insights
Thursday, August 31, 2023
Foghorn Therapeutics Announces First Patient ...
Benzinga Newsdesk
Thursday, August 10, 2023
Foghorn Therapeutics Said It Received Notice From Merck Regarding Termination Of Their Research Collaboration And Exclusive License Agreement Effective November 7, 2023; Foghorn Therapeutics Received A Total Of $20M From Merck Under The Agreement
Charles Gross
Monday, August 07, 2023
What 5 Analyst Ratings Have To Say About Foghorn Therapeutics
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Foghorn...
Benzinga Newsdesk
Friday, August 04, 2023
Foghorn Therapeutics' Q2 Cash, Cash Equivalen...
Benzinga Newsdesk
Foghorn Therapeutics Q2 EPS $(0.70) Beats $(0...
Benzinga Newsdesk
Thursday, July 06, 2023
Morgan Stanley Maintains Equal-Weight on Fogh...
Benzinga Newsdesk
Friday, June 30, 2023
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
Thursday, June 29, 2023
Schrödinger To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
Lisa Levin
Goldman Sachs Maintains Buy on Foghorn Therap...
Benzinga Newsdesk
Wednesday, June 28, 2023
Analyst Ratings for Foghorn Therapeutics
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Foghorn...
Benzinga Newsdesk
Foghorn Therapeutics Shifts Focus from Development Of Cancer Hopeful with Eye Cancer
Vandana Singh
Foghorn Therapeutics Plans To Discontinue The...
Benzinga Newsdesk
Thursday, June 08, 2023
What 6 Analyst Ratings Have To Say About Foghorn Therapeutics
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Foghorn...
Benzinga Newsdesk
Monday, June 05, 2023
The FDA Has Lifted Clinical Hold On Foghorn T...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch